Cite
Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells.
MLA
Hirai, Sachie, et al. “Trametinib Downregulates Survivin Expression in RB1-Positive KRAS-Mutant Lung Adenocarcinoma Cells.” Biochemical & Biophysical Research Communications, vol. 501, no. 1, June 2018, pp. 253–58. EBSCOhost, https://doi.org/10.1016/j.bbrc.2018.04.230.
APA
Hirai, S., Yamaguchi, M., Sakuma, Y., Sumi, T., Tanaka, Y., Tada, M., Takahashi, H., & Niki, T. (2018). Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells. Biochemical & Biophysical Research Communications, 501(1), 253–258. https://doi.org/10.1016/j.bbrc.2018.04.230
Chicago
Hirai, Sachie, Miki Yamaguchi, Yuji Sakuma, Toshiyuki Sumi, Yusuke Tanaka, Makoto Tada, Hiroki Takahashi, and Toshiro Niki. 2018. “Trametinib Downregulates Survivin Expression in RB1-Positive KRAS-Mutant Lung Adenocarcinoma Cells.” Biochemical & Biophysical Research Communications 501 (1): 253–58. doi:10.1016/j.bbrc.2018.04.230.